Drug maker led by Genenexers, and targeting Alzheimer's, Parkinson's and ALS, seeks $100 million IPO

A band of former Genentech employees has raised $350 million and gathered a portfolio of drugs targeting neurodegenerative diseases such as Alzheimer's, Parkinson's and Lou Gehrig's disease in just two and a half years — and now it's zeroing in on a $100 million initial public offering. Denali Therapeutics Inc. is the first sizable IPO by a Bay Area life sciences company this year and signals the resurgent hope in the industry that drugs can be found to tackle some of the toughest brain-wasting…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news